RAPT Therapeutics News

RAPT Therapeutics Analyst Ratings

BenzingaMay 14 08:00 ET

Analysts Offer Insights on Healthcare Companies: Lexeo Therapeutics, Inc. (LXEO), RAPT Therapeutics (RAPT) and Hookipa Pharma (HOOK)

TipRanksMay 14 04:40 ET

Maintaining Hold Rating on RAPT Therapeutics Amid Clinical Uncertainties and Financial Outlook

TipRanksMay 10 06:49 ET

RAPT Therapeutics Analyst Ratings

BenzingaMay 10 06:28 ET

Maintaining Hold Rating on RAPT Therapeutics Amidst Mixed Clinical Results and Regulatory Uncertainty

TipRanksApr 10 06:29 ET

RAPT Therapeutics Analyst Ratings

BenzingaApr 10 06:18 ET

RAPT Therapeutics Analyst Ratings

BenzingaMar 27 06:48 ET

Hold Rating on RAPT Therapeutics Amid Clinical Trial Uncertainties and Financial Concerns

TipRanksMar 11 00:46 ET

H.C. Wainwright Remains a Hold on RAPT Therapeutics (RAPT)

TipRanksMar 8 06:30 ET

Analysts Conflicted on These Healthcare Names: RAPT Therapeutics (RAPT), Eli Lilly & Co (LLY) and Sight Sciences (SGHT)

TipRanksMar 8 05:41 ET

H.C. Wainwright Cuts RAPT to Neutral, Cites Delays Due to Clinical Hold

Seeking AlphaFeb 21 13:51 ET

RAPT Therapeutics Analyst Ratings

BenzingaFeb 21 10:27 ET

JPMorgan Downgrades RAPT Therapeutics to Neutral From Overweight, Price Target Is $15

MT NewswiresFeb 21 07:16 ET

Analysts Offer Insights on Healthcare Companies: Globus Medical (GMED), Universal Health (UHS) and RAPT Therapeutics (RAPT)

TipRanksFeb 21 07:04 ET

RAPT Therapeutics Analyst Ratings

BenzingaFeb 20 14:12 ET

RAPT Therapeutics Analyst Ratings

BenzingaFeb 16 07:53 ET

RAPT Therapeutics Analyst Ratings

BenzingaFeb 15 06:16 ET

Buy Rating on RAPT Therapeutics Anchored by Promising Phase 2b AD Trial Prospects and Market Potential

TipRanksJan 13 08:08 ET

JP Morgan Maintains Overweight on RAPT Therapeutics, Raises Price Target to $35

BenzingaNov 30, 2023 14:08 ET

RAPT Therapeutics Analyst Ratings

BenzingaNov 30, 2023 14:06 ET